High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study.
Explore this paper's citation graph
Summary
The approximately 50% higher level of myo-inositol in Down's syndrome suggests a gene dose effect of the extra chromosome 21, where the human osmoregulatory sodium/myo- inositol cotransporter gene is located, which is similar to the earlier findings of high myoinositol levels in symptomatic Alzheimer's disease.
- Type
- article
- Published
- 1999-12-01
- Cited by
- 150
- References
- 48
- OpenAlex
- https://openalex.org/W1935009340
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:43644927
Keywords
Down syndrome, Inositol, Alzheimer's disease, Chromosome 21, Dementia
References
- Role of Increased Cerebral myo‐Inositol in the Dementia of Down Syndrome
- Down's syndrome fibroblasts exhibit enhanced inositol uptake.
- Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types
- The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome.
- Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease.
- Free and total lipid myo-inositol concentrations decrease with age in human brain.
- Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging
- Nature of mental retardation and dementia in Down syndrome: study with PET, CT, and neuropsychology.
- Decreased brain choline uptake in older adults. An in vivo proton magnetic resonance spectroscopy study.
- Regional in vivo proton magnetic resonance spectroscopy of brain
- Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease
- Lumbar cerebrospinal fluid choline in healthy aging and in Down's syndrome.
- Quantitative proton MR spectroscopic imaging of the human brain
- The molecular heterogeneity of protein kinase C and its implications for cellular regulation
- Evidence for a membrane defect in Alzheimer disease brain.
- Inositol phosphates and cell signalling
- Application of stable isotope tracer combined with mass spectrometric detection for studying myo-inositol uptake by cultured neurons from fetal mouse: effect of trisomy 16.
- Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease.
- Decline in cerebral glucose utilisation and cognitive function with aging in Down's syndrome.
- Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid.
Cited by
- Amino acid metabolic processes in the temporal lobes assessed by proton magnetic resonance spectroscopy (^1H MRS) in children with Down syndrome
- An MRI and H1-MRS study of dementia in down's syndrome and alzheimer's disease in the general population.
- Mild cognitive impairment: historical development and summary of research
- H Magnetic Resonance Spectroscopy Assessment of the Effects of Rivastigmine on Patients with moderate Alzheimer Disease
- Ts65Dn Mouse, a Down Syndrome Model, Exhibits Elevated myo-Inositol in Selected Brain Regions and Peripheral Tissues
- Coordinated Expression of Phosphoinositide Metabolic Genes during Development and Aging of Human Dorsolateral Prefrontal Cortex
- Decreased brain creatine levels in elderly apolipoprotein E ε4 carriers
- GABAB-GIRK2-mediated signaling in Down syndrome.
- MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease
- Effects of normal aging and SCN1A risk‐gene expression on brain metabolites: evidence for an association between SCN1A and myo‐inositol
- Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance
- The Partial Volume Effect in the Quantification of 1H Magnetic Resonance Spectroscopy in Alzheimer's Disease and Aging
- Myo‐inositol in Down syndrome amniotic fluid. A case‐control study
- In vivo 1H MRS study in microlitre voxels in the hippocampus of a mouse model of Down syndrome at 11.7 T
- 1H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging
- Measuring Brain Uptake and Incorporation into Brain Phosphatidylinositol of Plasma myo-[2H6]Inositol in Unanesthetized Rats: An Approach to Estimate In vivo Brain Phosphatidylinositol Turnover
- Quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology.
- Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy.
- Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy in Dementias
- Regional brain metabolite abnormalities in inherited prion disease and asymptomatic gene carriers demonstrated in vivo by quantitative proton magnetic resonance spectroscopy
Related papers
- Abnormal Protein Profiles in Hippocampus of Mouse Models of Down Syndrome: Similarities with Alzheimers Disease
- Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations
- Increased superoxide dismutase and Down's syndrome.
- Dissecting Alzheimer disease in Down syndrome using mouse models
- Down syndrome, Alzheimer's disease and the trisomy 16 mouse.
- Genetic dissection of down syndrome-associated alterations in APP/amyloid-β biology using mouse models
- Protein dysregulation in mouse hippocampus polytransgenic for chromosome 21 structures in the Down Syndrome Critical Region.
- Overexpression of copper-zinc superoxide dismutase in trisomy 21
- Genetic mapping of APP and amyloid‐β biology modulation by trisomy 21